Linked Life Data

16807576

Source:http://linkedlifedata.com/resource/pubmed/id/16807576

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1236
pubmed:dateCreated
2006-6-29
pubmed:abstractText
Statins are lipid-modifying drugs which dramatically lower the total and low-density lipoprotein cholesterol levels and have been shown in large clinical trials to reduce the rate of vascular events, including heart attacks, strokes, and death. For every 1% reduction in the LDL cholesterol level, the relative risk for major coronary heart disease events is reduced by approximately 1%. Since the landmark Scandinavian Simvastatin Survival Study (4S) was published in 1994, multiple further clinical trials have reinforced the benefits of treating large numbers of patients with statins with the emphasis on achieving low LDL cholesterol levels (currently 1.6 mmol/L) for the optimal management of patients at very high risk. However PHARMAC's actions since statins were first available have significantly impaired the optimal management of New Zealand patients. A review of the methods employed during the statin era is a useful exercise in understanding how PHARMAC functions and emphasises the point that rather than achieving low-cost prices for drugs, PHARMAC simply impedes the timely delivery of modern medicines to New Zealand patients.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1175-8716
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
119
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
U2033
pubmed:dateRevised
2007-3-13
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
PHARMAC and the statin debacle.
pubmed:affiliation
Greenlane Cardiovascular Service, Auckland City Hospital, Auckland. chrise@adhb.govt.nz
pubmed:publicationType
Journal Article